XPro1595® is a first-in-class Dominant Negative inhibitor of TNFα (DN-TNF) that we designed to act through a new and unique molecular mechanism of action.
In multiple animal models of autoimmune and neuroinflammatory diseases including rheumatoid arthritis, multiple sclerosis, asthma, uveitis, Parkinson’s, Alzheimer’s, and Crohn’s Disease XPro®1595 demonstrated potent activity against inflammation without suppressing natural immunity to infection. Immune suppression is the single most challenging side effect of current biologics therapies against TNF, which are clinically proven to be an effective treatment of inflammatory diseases. Annual sales of TNFα blockers currently exceed $16 billion.
XPro®1595 was designed using our Protein Design Automation® technology to function as a ligand and target receptor-specific inhibitor of TNFα, and thereby provide a greater safety margin and unique efficacy profile when compared to existing TNF inhibitor drugs. XPro®1595 is also engineered for superior pharmaceutical properties such as efficient microbial manufacturing, high stability and a convenient dosing schedule.
Xencor has engineered Dominant Negative inhibitors of other members of the TNF structural superfamily such as RANKL for the treatment of metastatic bone disease and osteoporosis, and BLyS/BAFF for lupus and other autoimmune diseases.